Cytomegalovirus infection following stem cell transplantation

Haematologica. 1999 Jun:84 Suppl EHA-4:46-9.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acyclovir / administration & dosage
  • Acyclovir / therapeutic use
  • Antibodies, Viral / blood
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use
  • Blood Donors
  • Cidofovir
  • Cytomegalovirus / immunology
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus / physiology
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / therapy
  • Cytomegalovirus Infections / transmission
  • Cytosine / administration & dosage
  • Cytosine / analogs & derivatives
  • Cytosine / therapeutic use
  • Foscarnet / administration & dosage
  • Foscarnet / therapeutic use
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Hematopoietic Stem Cells / virology
  • Humans
  • Immunocompromised Host
  • Immunotherapy, Adoptive
  • Leukocyte Transfusion
  • Organophosphonates*
  • Organophosphorus Compounds / administration & dosage
  • Organophosphorus Compounds / therapeutic use
  • Premedication
  • Risk Factors
  • Tissue Donors
  • Transfusion Reaction
  • Virus Latency

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • Foscarnet
  • Cytosine
  • Cidofovir
  • Ganciclovir
  • Acyclovir